| Literature DB >> 32192537 |
L M J Sanders1, T Hortobágyi2, E G A Karssemeijer3, E A Van der Zee4, E J A Scherder5, M J G van Heuvelen2.
Abstract
BACKGROUND: Potential moderators such as exercise intensity or apolipoprotein-E4 (ApoE4) carriership may determine the magnitude of exercise effects on physical and cognitive functions in patients with dementia (PwD). We determined the effects of a 24-week aerobic and strength training program with a low- and high-intensity phase on physical and cognitive function.Entities:
Keywords: ApoE4; Cognitive decline; Dementia; Dose-response relationship; Exercise intensity; Physical exercise
Mesh:
Year: 2020 PMID: 32192537 PMCID: PMC7082953 DOI: 10.1186/s13195-020-00597-3
Source DB: PubMed Journal: Alzheimers Res Ther Impact factor: 6.982
Fig. 1CONSORT flowchart
Sample characteristics at baseline
| Characteristic | Exercise ( | Control ( |
|---|---|---|
| Age (mean, SD) | 81.7 (7.16) | 82.1 (7.51) |
| Gender ( | 21 (53.8) | 22 (73.3)†i |
| Level of education ( | ||
| 1 = primary education only | 10 (25.6) | 8 (26.7) |
| 2 = secondary lower education | 25 (64.1) | 19 (63.3) |
| 3 = secondary higher education | 4 (10.3) | 3 (10.0) |
| Use of walking aid at baseline ( | 17 (43.6) | 19 (63.3) |
| Dementia diagnosis according to medical filea ( | ||
| 1 = Alzheimer’s disease (AD) | 14 (35.9) | 7 (23.3) |
| 2 = vascular dementia (VD) | 3 (7.7) | 1 (3.3) |
| 3 = mixed (AD+VD) | 3 (7.7) | 5 (16.7) |
| 4 = dementia with Lewy bodies (DLB) | 0 (0.0) | 1 (3.3) |
| 5 = others/unspecifiedb | 11 (28.2) | 12 (40.0) |
| MMSEc (mean, SD) | 21.4 (3.94) | 19.5 (4.77)†j |
| APOEd genotype ( | ||
| Carrier (e3/e4 and e4/e4) | 18 (46.2) | 12 (40.0) |
| Non-carrier (e2/e2, e2/e3, e3/e3) | 21 (53.8) | 18 (60.0) |
| Number of medications usede (mean, SD) | 5.2 (2.45) | 5.1 (2.74) |
| Use of beta blockers ( | 21 (53.8) | 14 (46.7) |
| DBIf (mean, SD) | 0.24 (0.38) | 0.22 (0.31) |
| FCIg (mean, SD) | 2.4 (1.66) | 2.7 (1.96) |
| BMIh (mean, SD) | 27.3 (3.53) | 27.6 (3.71) |
aN = 12 missing; bdiagnosis of “dementia” or “dementia syndrome”; cMini-Mental State Examination; dapolipoprotein E, within the carrier group N = 2 homozygote in exercise group, N = 1 homozygote in the control group; eN = 1 missing; fDrug Burden Index, N = 4 missing; gFunctional Comorbidity Index, N = 9 missing; hbody mass index. †Significant at p < 0.01. iχ (1) = 2.74, p = 0.098; jF(1, 67) = 3.03, p = 0.086
Descriptives, effect sizes, and results of ANCOVA for physical test scores
| Testa | Group | Baseline | 12 weeks | 24 weeks | Effect size, baseline-12 weeksb | Effect size, baseline-24 weeksb | ||
|---|---|---|---|---|---|---|---|---|
| 6MWT (m) | Exercise | 278 (89.4) | 280 (87.0) | 289 (95.0) | 0.18 [− 0.30, 0.65] | 2.73, | 0.08 [− 0.40, 0.56] | 1.36, |
| Control | 234 (88.6) | 222 (98.8) | 238 (87.4) | |||||
| SPPB (score) | Exercise | 8.75 (2.25) | 9.19 (2.37) | 8.96 (2.31) | 0.28 [− 0.20, 0.76] | 3.27c, | 0.16 [− 0.32, 0.64] | 2.46, |
| Control | 7.77 (2.08) | 7.58 (2.14) | 7.61 (2.41) | |||||
| 6MWS (m/s) | Exercise | 0.93 (0.31) | 0.93 (0.25) | 0.98 (0.25) | 0.04 [− 0.44, 0.52] | 1.46, | 0.41 [− 0.07, 0.90] | 12.83, |
| Control | 0.85 (0.22) | 0.84 (0.22) | 0.79 (0.27) | |||||
| FICSIT-4 (score) | Exercise | 3.36 (1.06) | 3.45 (1.19) | 3.30 (1.31) | 0.15 [− 0.33, 0.63] | 1.45, | − 0.15 [0.63, 0.33] | 0.09, |
| Control | 2.90 (1.40) | 2.81 (1.24) | 3.03 (1.35) | |||||
| TUG (s) | Exercise | 14.4 (6.24) | 13.6 (5.56) | 14.1 (6.62) | 0.23 [− 0.26, 0.71] | 2.35, | 0.17 [− 0.31, 0.66] | 1.43, |
| Control | 17.3 (5.56) | 17.8 (7.57) | 18.0 (7.20) | |||||
| Leg strength ( | Exercise | 202 (91.4) | 208 (98.4) | 214 (95.8) | 0.21 [− 0.27, 0.69] | 2.01, | 0.07 [− 0.41, 0.55] | 0.39, |
| Control | 188 (51.4) | 177 (58.5) | 194 (67.0) |
Values are mean (SD). N total = 69; N = 39 exercise vs. N = 30 control. Baseline-12 weeks is the low-intensity phase; baseline-24 weeks is the full study period (low-intensity and high-intensity phase). a6MWT 6-meter walk test, SPPB short physical performance Battery, 6MWS 6-meter walk speed; TUG Timed Up & Go. bCohen’s d with 95% CI, positive effect sizes are in favor of exercise group. cANCOVA with baseline as a covariate and use of walking aid as a factor, the main effect of group (exercise vs. control). **Significant at p < 0.001
Fig. 2Scores on STROOP, 6-meter walking speed and leg strength for the intervention vs. control group
Descriptives, effect sizes, and results of ANCOVA for cognitive test scores
| Testa | Group | Baseline | 12 weeks | 24 weeks | Effect sizeb, baseline-12 weeks | Effect sizeb, baseline-24 weeks | ||
|---|---|---|---|---|---|---|---|---|
| MMSE (score) | Exercise | 21.4 (3.94) | 21.0 (4.38) | 20.4 (4.77) | − 0.05 [− 0.53, 0.43] | 0.11, | − 0.04 [− 0.52, 0.44] | 0.04, |
| Control | 19.5 (4.77) | 19.4 (5.64) | 18.8 (5.88) | |||||
| TMTA (s) | Exercise | 121 (64.2) | 123 (63.7) | 126 (65.3) | − 0.03 [− 0.51, 0.45] | 0.51, | − 0.14 [− 0.62, 0.34] | 0.52, |
| Control | 156 (65.2) | 156 (61.1) | 153 (56.6) | |||||
| STROOP word (no. of correct responses) | Exercise | 54.3 (21.1) | 55.3 (19.7) | 53.5 (20.3) | 0.07 [− 0.41, 0.55] | 0.64, | 0.13 [− 0.35, 0.61] | 1.35, |
| Control | 50.9 (22.5) | 50.5 (22.0) | 47.4 (20.1) | |||||
| STROOP color (no. of correct responses) | Exercise | 41.3 (14.8) | 43.9 (17.0) | 43.3 (16.3) | 0.17 [− 0.31, 0.65] | 1.93, | 0.03 [− 0.45, 0.51] | 0.47, |
| Control | 36.4 (17.6) | 36.3 (18.0) | 38.0 (15.4) | |||||
| STROOP color-word (no. of correct responses) | Exercise | 17.6 (10.4) | 16.5 (10.8) | 17.2 (10.7) | − 0.24 [− 0.72, 0.24] | 0.45, | − 0.37 [− 0.85, 0.12] | 0.61, |
| Control | 13.5 (9.05) | 14.9 (8.63) | 16.8 (8.83) | |||||
| STROOP interference quotient | Exercise | 3.46 (3.18) | 4.04 (3.68) | 3.56 (2.81) | − 0.49 [− 0.98, 0.00] | 4.29, | − 0.42 [− 0.90, 0.07] | 2.13, |
| Control | 4.19 (3.99) | 3.14 (2.21) | 3.00 (2.21) | |||||
| DSFW (no. of correct responses) | Exercise | 6.79 (1.77) | 7.11 (2.14) | 6.67 (1.80) | 0.15 [− 0.33, 0.63] | 0.96, | − 0.13 [− 0.61, 0.35] | 0.40, |
| Control | 6.53 (1.55) | 6.58 (1.67) | 6.64 (1.91) | |||||
| DSBW (no. of correct responses) | Exercise | 4.00 (1.39) | 4.00 (1.54) | 4.01 (1.31) | − 0.03 [− 0.51, 0.45] | 0.20, | 0.10 [− 0.38, 0.58] | 0.15, |
| Control | 4.17 (1.32) | 4.21 (1.48) | 4.04 (1.60) | |||||
| VMSFW (no. of correct responses) | Exercise | 5.78 (1.95) | 5.50 (1.57) | 5.23 (1.50) | 0.04 [− 0.43, 0.52] | 2.01, | − 0.05 [− 0.53, 0.43] | 1.20, |
| Control | 4.96 (1.80) | 4.60 (1.82) | 4.50 (2.05) | |||||
| VMSBW (no. of correct responses) | Exercise | 4.31 (2.05) | 4.23 (1.93) | 4.56 (1.71) | 0.14 [− 0.34, 0.62] | 0.71, | 0.33 [− 0.16, 0.81] | 2.92, |
| Control | 4.30 (1.86) | 3.94 (1.94) | 3.93 (1.98) | |||||
| Fluency (no. of correct responses) | Exercise | 18.9 (7.73) | 18.3 (8.27) | 21.6 (8.49) | − 0.06 [− 0.54, 0.42] | 0.03, | 0.13 [− 0.35, 0.61] | 2.00, |
| Control | 14.7 (9.39) | 14.6 (9.95) | 16.3 (9.52) |
Values are mean (SD). N total = 69; N = 39 exercise vs. N = 30 control. Baseline-12 weeks is the low-intensity phase; baseline-24 weeks is the full study period (low-intensity and high-intensity phase). aMMSE Mini-Mental State Examination, TMTA Trail Making Test A, DSFW Digit Span Forward, DSBW Digit Span Backward, VMSFW Visual Memory Span Forward, VMSBW Visual Memory Span Backward, Fluency phonemic fluency test. bCohen’s d with 95% CI, positive effect sizes are in favor of exercise group. dANCOVA with baseline as a covariate, the main effect of group (exercise vs. control). *Significant at p < 0.05